

Supplementary materials

Table S1 List of Independent Ethics Committees and Institutional Review Boards

ACLIFORM (NCT01462942)^a	
Country	Name and address of IEC/IRB
Austria	Ethikkommission der Medizinischen (central) Universität Graz, Auenbruggerplatz 2, 8036 Graz
	Ethics committee of the Medical University Graz (local) Auenbruggerplatz 2, 8036 Graz
	Ethics committee of the country Salzburg (local) Sebastian- Stief-Gasse 2, 5010 Salzburg
Belgium	Ethisch Comité UZA, Wilrijkstraat 10, Edegem 2650
Bulgaria	Ethics Committee for Multicenter Trials (ECMT) (central) 5, “Sveta Nedelya” Square, 1000 Sofia
	Local Ethics Committee UMHAT Aleksandrovska EAD, 3, Georgi Sofiyski Str. 1431 Sofia
	Local Ethics Committee SHATTPD-Ruse EOOD, 1, Aleya Lilia Str. 7002 Ruse
	Local Ethics Committee SHATPFD-Sofia District EOOD, 309, “Slivnitsa” Blvd, 1234 Sofia

	Local Ethics Committee DCC Sveta Anna EOOD, 1, Dimitar Mollov Str. 1709 Sofia
	Local Ethics Committee DCC “Akta Medika” EOOD, 60, “Nikola Petkov” Str., 5400 Sevlievo
Croatia	Agency for Medicinal Product and Medical Devices of Croatia Central Ethics Committee, Ksaverska cesta 4, Zagreb, 10000
Czech Republic	Multicentricka eticka komise Fakultni nemocnice u sv. Anny v Brne, Vystavni 17/19, Brno, 656
Denmark	De Videnskabsetiske Komitéer for Region Hovedstaden Kongens Vænge 2, 3400 Hillerød
Finland	Keski-Suomen sairaanhoitopiiri, Eettinen toimikunta Sairaan hoitopiirin toimisto Rak. 6/2, Keskussairaalantie 19, 40620 Jyväskylä
France	Comité de Protection des Personnes Sud Ouest et Outre Mer III Place Amélie Raba-Léon, Groupe Hospitalier Pellegrin – Service de Pharmacologie Clinique, Bât 1 A, Bordeaux cedex, 33076
Germany	Landesärztekammer Rheinland-Pfalz (central), Postfach 29 26, 55019 Mainz
	Landesamt für Gesundheit und Soziales Berlin (local) Geschäftsstelle der Ethik-Kommission des Landes Berlin, Fehrbelliner Platz 1, 10707 Berlin
	Ethik-Kommission des Landes Sachsen-Anhalt (local) Geschäftsstelle, Kühnauer Str. 70, 06846 Dessau-Roßlau

	Ethik-Kommission der Ärztekammer Westfalen-Lippe und der Medizinischen Fakultät der Westfälischen Wilhelms-Universität Münster (local) Gartenstr. 210–214, 48147 Münster
	Landesärztekammer Hessen, Ethikkommission (local) Im Vogelsang 3, 60488 Frankfurt am Main
	Sächsische Landesärztekammer, Ethikkommission (local) Schützenhöhe 16–18, 01099 Dresden
	Ärztekammer Hamburg, Ethikkommission (local) Humboldtstr. 67a, 22083 Hamburg
	Landesärztekammer Rheinland-Pfalz, Ethikkommission (local) Deutschhausplatz 3, 55116 Mainz
	Ärztekammer Nordrhein, Ethikkommission (local) Tersteegenstr. 9, 40474 Düsseldorf
	Ethikkommission der Medizinischen Fakultät der Universität Rostock (local) Institut für Rechtsmedizin, St. Georg-Str. 108
	Ärztekammer Niedersachsen, Ethikkommission (local) Berliner Allee 20, 30175 Hannover
	Bayerische Landesärztekammer, Ethikkommission (local) Mühlbaurstr. 16, 81677 München
Hungary	Egészségügyi Tudományos Tanács Klinikai Farmakológiai Etikai Bizottsága Arany J. u. 6–8, Budapest, H-1051

Italy	Comitato Etico Locale per la Sperimentazione Clinica dei Medicinali dell'Azienda Ospedaliero ra Universitaria ria Senese di Siena (central) c/o Farmacia AOUS Viale Bracci, Siena, 53100
	Comitato Etico Unico per la Provincia di Parma (local) Via Gramsci, 14, Parma, 43100
	Comitato per la Sperimentazione Clinica Medicinali dell'Azienda Ospedaliero Universitaria Pisana di Pisa (local) Via Roma 67, Pisa, 56100
	Comitato Etico dell'Azienda Ospedaliero Universiitaria S.Martino di Genova (local) Largo Rosanna Benzi, 10, Genova, 16132
Republic of Korea	IRB of Ewha Womans University Mokdong Hospital (local) 1071, Anyangcheon-ro, YangCheon-Ku, Seoul, 158-710
	IRB of Korea University Anam Hospital (local) 73 Inchon-ro, Seongbuk-Gu, Seoul, 136-705
	IRB of Hallym University Sacred Heart Hospital (local) 896 Pyeongchon-dong, Dongan-gu, Anyang-si, 431-070
	IRB of The Catholic University of Korea (local) Seoul St.Mary's Hospital 222 Banpo-Daero, Seocho-gu, Seoul, 137-701
	IRB of Soonchunhyang University Bucheon Hospital (local) 1174 Joong-dong, Wonmi-gu, Buchon-si, 420-767
	IRB of Korea University Guro Hospital (local) 148 Gurodong-ro, Guro-Gu, Seoul, 152-703

	IRB of Yonsei University Wonju Christian Hospital (local) 20 Ilsan-Ro, Wonju-Si, 220-701
	IRB of Seoul National Hospital (local) 101 Daehak-ro Jongno-gu, Seoul, 110-744
Netherlands	METC Catharina ziekenhuis Michelangelo laan 2, Eindhoven, 5623 EJ
Poland	Komisja Bioetyczna przy Instytucie Gruzlicy I Chorob Pluc ul. Plocka 26, Warszawa, 01-138
Romania	Comisia Nationala de Etica Str. Aviator Sanatescu Nr. 48, Bucuresti, Sector 1,01
Russian Federation	Ethical Council at the MoH of RF (central) 3 Rakhmanovsky Pereulok, Moscow, 127994
	LEC at City Clinical Hospital #23 n.a. Medsantrud (local) 11, Yauzskaya str, Moscow, 109240
	LEC FA of HealthCare and SD StP Rheumatology Clinical Hosp.#25 (local) 47, Piskarevsky prospect, St. Petersburg, 195067
	LEC at SRI of Therapy of Siberian branch of Russian Academy of Medical Sciences (local) 175/1, B.Bogatkova str, Novosibirsk, 630089
	LEC at StP SMU n.a. acad. I.P. Pavlov (local) 10, Rentgena str.Saint-Petersburg, 197101
	LEC at FSd ESMC of presed. RF City Hospital #17 (local) Volynskaya, 7, Moscow, 119620

Slovakia	Fakultná nemocnica s poliklinikou F.D. Roosevelta (central) Nám. L. Svobodu 1, 975 17 Banská Bystrica
	Nitriansky samosprávny kraj Úrad Nitrianskeho samosprávneho kraja Etická komisia (local) Štefánikova tr. 69, 949 01 Nitra
	Bratislavský samosprávny kraj, Úrad samosprávneho kraja, Etická komisia (local) Sabinovská 16, P.O. Box 106, 820 05 Bratislava 25
	Košický samosprávny kraj, Úrad Košického samosprávneho kraja Etická komisia (local) Námestie Maratónu mieru 1, 042 66 Košice
	NsP Sv. Jakuba, n.o. (local) Bardejov, ul. Sv. Jakuba 21, 085 01 Bardejov
	EK-Narodny ustav TBC, pľucnych chorob a hrudnikovej chirurgie (local) Vysne Hagy, Vysne Hagy, 05984
South Africa	Pharma Ethics (local) 123 Amcor Road, Lyttelton Manor 0157
	University of Cape Town Ethics Committee (local) Faculty of Health Sciences Research EC, E52-24 Old Main Building, Groote Schuur Hospital, Observatory, Cape Town, 7925
	University of Stellenbosch Ethics Committee (local) Faculty of Health Sciences, Francie van Zijl Drive, Cape Town, 7505
	University of Pretoria, Research Ethics Committee (local) 31 Bophelo Road, HW Snyman South Building, Level 2, Room 2:34, Pretoria, Gauteng, 0001

Spain	CEIC Hospital Universitario Puerta de Hierro Majadahonda, Planta 1ª, Pasillo unidades, administrativas de servicios (central) c/ Manuel de Falla, 1, Majadahonda, 28222
	CEIC Institut Municipal d'Assistència Sanitària (local) C/ Doctor Aiguader, 88 Edifici PRBB Barcelona, 08003
	Comité Ético de Investigación Clínica de Asturias (local) C/ Celestino Villamil, s/n Oviedo, 33006
	CEIC Hospital virgen de la Macarena (local) Dirección: Avda. Dr. Fedriani, 3 – Unidad de Investigación 2ª planta Sevilla, 41071
	CEIC del Complejo Hospitalario de Cáceres (local) Avda. Pablo Naranjo s/n Caceres, 10003
	CEIC del IDIAP Jordi Gol i Gurina (local) Gran Via de les Corts Catalanes, 587 atico Barcelona, 08007
	CEIC Hospital Germans Trias i Pujol (local) Ctra. Canyet, s/n Badalona, 08916
	CEIC Hospital general Carlos Haya (local) Avda. Carlos Haya, s/n Málaga, 29010
Sweden	Regionala etikprövningsnämnden i Lund Box 133, Östra Vallgatan, 14/Östervångsvägen 1, Lund, 22100
Ukraine	Central Ethics Commission of the Ministry of Health of Ukraine (central) 5, Narodnogo Opolchennya St., Kyiv, 03680

	LEC "Kharkiv City Clinical Hospital # 13" (local) 137, Gagarin Av. Kharkiv, 61035
	LEC SI "National Institute of Phthiisology and Pulmonology named F.G.Yanovskyy of AMS of Ukr (local) 10, Amosova Str., Kyiv, 03680
United Kingdom	NRES Committee North West (central) 3rd Floor, Barlow House, 4 Minshull Street, Manchester, M1 3DZ
	Bart's Health NHS Trust, Joint Research and Development Office (local) Queen Mary Innovation Centre, 5 Walden Street, London, E1 2EF
	The Royal Wolverhampton Hospitals NHS Trust, Research & Development Directorate (local) The Chestnuts, Wolverhampton, West Midlands, WV10 0QP
	Cambridge University Hospitals NHS Foundation Trust (local) Addenbrookes Hospital, Hills Road, Cambridge, CB2 0QQ
	Hull & East Yorkshire Hospitals NHS Trust (local) Research & Development Department, 2nd Floor Daisy Building, Castle Hill Hospital, Castle Road, Cottingham, East Yorkshire, HU16 5JQ
	Bradford Teaching Hospitals NHS Foundation Trust (local) Bradford Royal Infirmary, Room 6, Pharmacy Stores, Gate 7, Smith Lane, Bradford West Yorkshire, BD9 6RJ
	NRES Committee West Midlands (local) Prospect House, Fishing Line Road, Enfield, Redditch, B97 6EW
	NRES Committee South Central (local) Building L27, University of Reading, London Road, Reading, RG1 5AQ

	North Tees & Hartlepool NHS Foundation Trust – R&D (local) Hardwick Road, Stockton on Tees, TS19 8PE
	Wirral University Teaching Hospital NHS Foundation Trust (local) Arrowe Park Hospital, Arrowe Park Road, Upton, Wirral, CH49 5PE
	NHS Royal Victoria Infirmary (local) Queen Victoria Road, Newcastle Upon Tyne, Newcastle, NE1 4LP
AUGMENT (NCT01437397)	
Australia	Bellberry Human Research Ethics Committee 229 Greenhill Road, Dulwich SA 5065, Australia
	Flinders Clinical Research Ethics Committee Bedford Park SA 5042, Australia
	Gold Coast Health Service District Human Research Ethics Committee 108 Nerang Street, Southport Qld 4215, Australia
	Human Research Ethics Committee - D St. Vincent's Health Melbourne, PO Box 2900, Fitzroy, Vic, 3065, Australia
	Hunter New England Human Research Ethics Committee Locked Bag 1, New Lambton NSW 2305, Australia
	Royal Adelaide Hospital Research Ethics Committee North Terrace, Adelaide SA 5000, Australia

Canada	IRB Services (Institutional Review Board Services) (central) 372 Hollandview Trail, Suite 300 Aurora, Ontario L4G 0A5, Canada
	Concordia Hospital Ethics Committee (local) Concordia Hospital, 1095 Concordia Avenue, Winnipeg, Manitoba, R2K 3S8, Canada
	University of British Columbia, Clinical Research Ethics Board Office (local) Room 210, Research pavilion, 828 West 10th Avenue, Vancouver, British Columbia, V5Z 1L8, Canada
	University of Saskatchewan Biomedical, Ethics Review Board (local) Research Ethics Office, University of Saskatchewan, Box 5000 RPO University, Saskatoon, Saskatchewan S7N 4J8 Canada
New Zealand	Multi-region Ethics Committee c/- Ministry of Health, PO Box 5013, 1 the Terrace, Wellington, New Zealand
USA	Quorum Institutional Review Board (central) 1601 Fifth Avenue, Suite 1000, Seattle, WA 98101, USA
	Creighton University IRB (local) 2500 California Plaza, Omaha, NE 68178, USA
	Greater LA-VA IRB (local) 11301 Wilshire Blvd., Building 114 Room 325, Los Angeles, CA 90073, USA
	Human Studies Subcommittee Bay Pines VA Healthcare System (local) Research and Development Service (151), 10000 Bay Pines Blvd., Bay Pines, FL 33744, USA
	Institutional Review Board, University of Texas Health Science Center at Tyler (local) 11937 US Highway 271, Tyler, TX 75708, USA

Kansas City Veterans Affairs Medical Center IRB (local) 4801 East Linwood Blvd., #151, Kansas City, MO 64128, USA
Mayo Clinic Office for Human Research Protection Institutional Review Board (IRB) (local) 201 Building Room 4-60, 200 1st Street SW, Rochester, MN 55905, USA
Mercy St. Vincent Medical Center Adult Investigational Review Board (local) 2213 Cherry St., Toledo, OH 43608, USA
Sparks Institutional Review Board (local) 1001 Towson Avenue, PO Box 2406, Fort Smith, AR 72902-2406, USA
St. Luke's IRB (local) 232 S. Woods Mill Rd., Chesterfield, MO 63017, USA
UC Davis Medical Center IRB (local) CTSC Building, 2921 Stockton Blvd, Suite 1400, Room 1429, Sacramento, CA 95817
University of California San Diego Human Research Protections Program (local) 9500 Gilman Drive, Mail Code 0052, La Jolla, CA 92093-0052, USA
University of Illinois College of Medicine of Peoria Institutional Review Board (local) One Illini Drive, Box 1649, Peoria, IL 61656-1649, USA
Wake Forest University Health Sciences Office of Research / Institution Review Board (local) Medical Center Blvd., Winston-Salem, NC 27157, USA
Western Institutional Review Board (local) 3535 7th Avenue SW, Olympia, WA 98502, USA

Notes: ^aAdapted from Singh D, Jones PW, Bateman ED, et al. Efficacy and safety of acclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study.

BMC Pulm Med. 2014;14(1):178. Creative Commons license and disclaimer available from:

<http://creativecommons.org/licenses/by/4.0/legalcode>"<http://creativecommons.org/licenses/by/4.0/legalcode>.¹

Abbreviations: IEC, independent ethics committee; IRB, Institutional Review Board.

Table S2 Baseline patient demographics and characteristics analyzed by baseline airflow obstruction severity (safety population)

	Moderate airflow obstruction ^a					Severe airflow obstruction ^b				
	AB/FF 400/12 µg (n=418)	AB 400 µg (n=410)	FF 12 µg (n=434)	Placebo (n=293)	Total (n=1,555)	AB/FF 400/12 µg (n=298)	AB 400 µg (n=304)	FF 12 µg (n=275)	Placebo (n=227)	Total (n=1,104)
Age, mean years (SD)	63.1 (8.7)	63.7 (9.0)	63.5 (8.3)	63.5 (8.6)	63.4 (8.6)	63.7 (8.2)	63.6 (7.7)	63.6 (8.0)	64.0 (8.5)	63.7 (8.1)
≥65 years, n (%)	183 (43.8)	197 (48.0)	207 (47.7)	135 (46.1)	722 (46.4)	142 (47.7)	143 (47.0)	128 (46.5)	111 (48.9)	524 (47.5)
Male, n (%)	242 (57.9)	246 (60.0)	251 (57.8)	172 (58.7)	911 (58.6)	185 (62.1)	191 (62.8)	171 (62.2)	138 (60.8)	685 (62.0)
Caucasian, n (%)	390 (93.3)	385 (93.9)	408 (94.0)	284 (96.9)	1,467 (94.3)	279 (93.6)	285 (93.8)	259 (94.2)	210 (92.5)	1,033 (93.6)
Current smoker, n (%)	209 (50.0)	205 (50.0)	201 (46.3)	139 (47.4)	754 (48.5)	143 (48.0)	145 (47.7)	144 (52.4)	120 (52.9)	552 (50.0)
Mean cigarette consumption, pack-years (SD)	43.9 (22.4)	43.5 (24.4)	45.1 (22.4)	49.6 (26.9)	45.2 (23.9)	50.4 (28.2)	46.5 (22.3)	46.7 (22.5)	48.4 (26.1)	48.0 (24.9)
Baseline FEV ₁ , L (SD)	1.652 (0.482)	1.617 (0.502)	1.614 (0.485)	1.660 (0.520)	1.634 (0.496)	1.026 (0.318)	1.045 (0.314)	1.054 (0.320)	1.035 (0.350)	1.040 (0.324)
Percent predicted FEV ₁ at baseline (SD), %	57.9 (10.7)	56.5 (10.6)	56.7 (11.2)	56.7 (10.3)	57.0 (10.8)	36.0 (8.2)	36.4 (8.3)	36.5 (8.1)	35.7 (8.0)	36.2 (8.2)

Baseline Dyspnea Index focal score (SD)	6.8 (2.0)	6.8 (2.1)	6.7 (2.3)	6.9 (2.2)	6.8 (2.2)	5.8 (2.0)	6.1 (2.1)	6.0 (2.0)	5.9 (2.2)	6.0 (2.1)
Number of exacerbations in previous 12 months, mean (SD)	0.4 (0.8)	0.4 (0.7)	0.3 (0.8)	0.3 (0.6)	0.4 (0.8)	0.5 (1.0)	0.6 (1.0)	0.5 (0.8)	0.4 (0.7)	0.5 (0.9)
0, n (%)	301 (72.0)	307 (74.9)	332 (76.5)	229 (78.2)	1,169 (75.2)	199 (66.8)	191 (62.8)	171 (62.2)	162 (71.4)	723 (65.5)
≥1, n (%)	117 (28.0)	103 (25.1)	102 (23.5)	64 (21.8)	386 (24.8)	99 (33.2)	113 (37.2)	104 (37.8)	65 (28.6)	381 (34.5)

Notes: ^aGOLD Stage II (moderate): FEV₁ ≥50% to <80% predicted and FEV₁/FVC <0.70.² ^bGOLD Stage III (severe): FEV₁ ≥30% to <50% predicted and FEV₁/FVC <0.70.²

Abbreviations: AB, aclidinium bromide; FEV₁, forced expiratory volume in 1 second; FF, formoterol fumarate.

Table S3 Baseline patient demographics and characteristics analyzed by patient age (safety population)

	Patients aged <65 years					Patients aged ≥65 years				
	AB/FF 400/12 µg (n=393)	AB 400 µg (n=376)	FF 12 µg (n=379)	Placebo (n=276)	Total (n=1,424)	AB/FF 400/12 µg (n=327)	AB 400 µg (n=346)	FF 12 µg (n=337)	Placebo (n=250)	Total (n=1,260)
Age, mean years (SD)	57.1 (5.2)	57.2 (5.5)	57.2 (5.1)	57.1 (5.4)	57.2 (5.3)	70.9 (4.7)	70.7 (4.6)	70.6 (4.3)	71.0 (4.5)	70.8 (4.5)
Male, n (%)	229 (58.3)	223 (59.3)	213 (56.2)	160 (58.0)	825 (57.9)	200 (61.2)	221 (63.9)	211 (62.6)	153 (61.2)	785 (62.3)
Caucasian, n (%)	369 (93.9)	348 (92.6)	359 (94.7)	260 (94.2)	1,336 (93.8)	303 (92.7)	329 (95.1)	314 (93.2)	240 (96.0)	1,186 (94.1)
Current smoker, n (%)	250 (63.6)	235 (62.5)	239 (63.1)	183 (66.3)	907 (63.7)	104 (31.8)	118 (34.1)	111 (32.9)	80 (32.0)	413 (32.8)
Mean cigarette consumption, pack-years (SD)	42.8 (22.3)	41.5 (20.9)	43.3 (20.5)	45.5 (22.5)	43.1 (21.5)	51.2 (27.4)	48.5 (25.9)	48.6 (23.9)	53.0 (29.9)	50.1 (26.7)
Severity of airflow obstruction, n (%)										
Stage II (Moderate) ^a	235 (59.8)	213 (56.6)	227 (60.2)	158 (57.2)	833 (58.6)	183 (56.1)	197 (57.6)	207 (61.4)	135 (54.4)	722 (57.6)
Stage III (Severe) ^b	156 (39.7)	161 (42.8)	147 (39.0)	116 (42.0)	580 (40.8)	142 (43.6)	143 (41.8)	128 (38.0)	111 (44.8)	524 (41.8)
Baseline FEV ₁ , L (SD)	1.512 (0.538)	1.461 (0.538)	1.514 (0.525)	1.504 (0.591)	1.498 (0.545)	1.238 (0.465)	1.284 (0.481)	1.265 (0.460)	1.247 (0.466)	1.260 (0.468)

Percent predicted FEV ₁ at baseline (SD), %	49.7 (14.7)	47.6 (13.8)	50.0 (14.7)	47.8 (14.3)	48.9 (14.4)	47.4 (14.3)	48.2 (14.1)	47.7 (13.7)	46.9 (13.9)	47.6 (14.0)
Baseline Dyspnea Index focal score (SD)	6.2 (2.1)	6.6 (2.2)	6.3 (2.2)	6.5 (2.3)	6.4 (2.2)	6.6 (2.0)	6.4 (2.1)	6.6 (2.2)	6.5 (2.2)	6.5 (2.1)
Number of exacerbations in previous 12 months, mean (SD)	0.5 (0.9)	0.5 (0.8)	0.5 (0.9)	0.3 (0.7)	0.4 (0.8)	0.4 (0.9)	0.5 (0.9)	0.4 (0.7)	0.3 (0.6)	0.4 (0.8)
0, n (%)	270 (68.7)	254 (67.6)	261 (68.9)	212 (76.8)	997 (70.0)	233 (71.3)	251 (72.5)	248 (73.6)	184 (73.6)	916 (72.7)
≥1, n (%)	123 (31.3)	122 (32.4)	118 (31.1)	64 (23.2)	427 (30.0)	94 (28.7)	95 (27.5)	89 (26.4)	66 (26.4)	344 (27.3)

Notes: ^aGOLD Stage II (moderate): FEV₁ ≥50% to <80% predicted and FEV₁/FVC <0.70.² ^bGOLD Stage III (severe): FEV₁ ≥30% to <50% predicted and FEV₁/FVC <0.70.²

Abbreviations: AB, aclidinium bromide; FEV₁, forced expiratory volume in 1 second; FF, formoterol fumarate; FVC, forced vital capacity.

Table S4 Baseline patient demographics and characteristics analyzed by exacerbation history (safety population)

	No exacerbations					≥1 exacerbations				
	AB/FF 400/12 µg (n=503)	AB 400 µg (n=505)	FF 12 µg (n=509)	Placebo (n=396)	Total (n=1,913)	AB/FF 400/12 µg (n=217)	AB 400 µg (n=217)	FF 12 µg (n=207)	Placebo (n=130)	Total (n=771)
Age, mean years (SD)	63.7 (8.7)	64.2 (8.2)	63.6 (8.4)	63.7 (8.6)	63.8 (8.5)	62.6 (8.1)	62.5 (9.0)	63.3 (7.8)	63.9 (8.4)	63.0 (8.3)
≥65 years, n (%)	233 (46.3)	251 (49.7)	248 (48.7)	184 (46.5)	916 (47.9)	94 (43.3)	95 (43.8)	89 (43.0)	66 (50.8)	344 (44.6)
Male, n (%)	296 (58.8)	322 (63.8)	310 (60.9)	241 (60.9)	1,169 (61.1)	133 (61.3)	122 (56.2)	114 (55.1)	72 (55.4)	441 (57.2)
Caucasian, n (%)	461 (91.7)	472 (93.5)	475 (93.3)	373 (94.2)	1,781 (93.1)	211 (97.2)	205 (94.5)	198 (95.7)	127 (97.7)	741 (96.1)
Current smoker, n (%)	251 (49.9)	251 (49.7)	244 (47.9)	208 (52.5)	954 (49.9)	103 (47.5)	102 (47.0)	106 (51.2)	55 (42.3)	366 (47.5)
Mean cigarette consumption, pack-years (SD)	48.0 (26.0)	46.4 (24.7)	46.4 (23.1)	50.1 (26.6)	47.6 (25.1)	43.5 (22.5)	41.3 (20.6)	44.4 (20.3)	46.2 (26.3)	43.6 (22.2)
Severity of airflow obstruction, n (%)										
Stage II (Moderate) ^a	301 (60.0)	307 (61.3)	332 (65.4)	229 (58.1)	1169 (61.4)	117 (53.9)	103 (47.5)	102 (49.5)	64 (49.2)	386 (50.1)
Stage III (Severe) ^b	199 (39.6)	191 (38.1)	171 (33.7)	162 (41.1)	723 (38.0)	99 (45.6)	113 (52.1)	104 (50.5)	65 (50.0)	381 (49.5)

Baseline FEV ₁ , L (SD)	1.410 (0.540)	1.410 (0.507)	1.447 (0.510)	1.414 (0.566)	1.421 (0.529)	1.335 (0.482)	1.297 (0.538)	1.272 (0.491)	1.286 (0.487)	1.299 (0.501)
Percent predicted FEV ₁ at baseline (SD), %	49.5 (14.6)	48.6 (13.8)	50.1 (14.1)	47.9 (14.3)	49.1 (14.2)	46.7 (14.4)	46.2 (14.1)	45.9 (14.4)	45.8 (13.6)	46.2 (14.2)
Baseline Dyspnea Index focal score (SD)	6.6 (2.1)	6.6 (2.2)	6.6 (2.2)	6.6 (2.2)	6.6 (2.2)	6.0 (1.9)	6.2 (2.1)	6.0 (2.2)	6.1 (2.1)	6.0 (2.1)
Number of exacerbations in previous 12 months, mean (SD)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1.5 (1.0)	1.5 (0.9)	1.4 (0.9)	1.3 (0.6)	1.5 (0.9)

Notes: ^aGOLD Stage II (moderate): FEV₁ ≥50% to <80% predicted and FEV₁/FVC <0.70.² ^bGOLD Stage III (severe): FEV₁ ≥30% to <50% predicted and FEV₁/FVC <0.70.²

Abbreviations: AB, aclidinium bromide; FEV₁, forced expiratory volume in 1 second; FF, formoterol fumarate.

Table S5 Baseline patient demographics and characteristics analyzed by patient sex (safety population)

	Female					Male				
	AB/FF 400/12 µg (n=291)	AB 400 µg (n=278)	FF 12 µg (n=292)	Placebo (n=213)	Total (n=1,074)	AB/FF 400/12 µg (n=429)	AB 400 µg (n=444)	FF 12 µg (n=424)	Placebo (n=313)	Total (n=1,610)
Age, mean years (SD)	63.4 (8.8)	63.3 (8.7)	62.3 (8.2)	63.1 (8.2)	63.0 (8.5)	63.4 (8.3)	63.9 (8.3)	64.3 (8.1)	64.2 (8.8)	63.9 (8.4)
≥65 years, n (%)	127 (43.6)	125 (45.0)	126 (43.2)	97 (45.5)	475 (44.2)	200 (46.6)	221 (49.8)	211 (49.8)	153 (48.9)	785 (48.8)
Caucasian, n (%)	278 (95.5)	270 (97.1)	279 (95.5)	208 (97.7)	1,035 (96.4)	394 (91.8)	407 (91.7)	394 (92.9)	292 (93.3)	1,487 (92.4)
Current smoker, n (%)	156 (53.6)	135 (48.6)	147 (50.3)	119 (55.9)	557 (51.9)	198 (46.2)	218 (49.1)	203 (47.9)	144 (46.0)	763 (47.4)
Mean cigarette consumption, pack-years (SD)	42.5 (22.7)	40.0 (21.1)	41.7 (19.6)	47.0 (24.3)	42.5 (22.0)	49.5 (26.2)	47.9 (24.7)	48.6 (23.6)	50.6 (27.9)	49.0 (25.5)
Severity of airflow obstruction, n (%)										
Stage II (Moderate) ^a	176 (60.7)	164 (59.2)	183 (62.9)	121 (57.1)	644 (60.2)	242 (56.4)	246 (55.8)	251 (59.3)	172 (55.1)	911 (56.8)
Stage III (Severe) ^b	113 (39.0)	113 (40.8)	104 (35.7)	89 (42.0)	419 (39.2)	185 (43.1)	191 (43.3)	171 (40.4)	138 (44.2)	685 (42.7)
Baseline FEV ₁ , L (SD)	1.157 (0.414)	1.110 (0.373)	1.163 (0.421)	1.097 (0.364)	1.135 (0.397)	1.544 (0.533)	1.543 (0.528)	1.558 (0.505)	1.576 (0.570)	1.554 (0.532)

Percent predicted FEV ₁ at baseline (SD), %	49.2 (14.5)	47.8 (14.0)	48.9 (14.8)	46.6 (13.5)	48.2 (14.3)	48.3 (14.6)	48.0 (13.9)	48.9 (14.0)	47.9 (14.6)	48.3 (14.2)
Baseline Dyspnea Index focal score (SD)	6.1 (2.0)	6.6 (2.2)	6.2 (2.2)	6.6 (2.0)	6.4 (2.1)	6.6 (2.1)	6.4 (2.1)	6.6 (2.2)	6.4 (2.3)	6.5 (2.2)
Number of exacerbations in previous 12 months, mean (SD)	0.4 (0.8)	0.5 (0.9)	0.5 (0.9)	0.3 (0.7)	0.5 (0.9)	0.5 (0.9)	0.4 (0.8)	0.4 (0.7)	0.3 (0.7)	0.4 (0.8)
0, n (%)	207 (71.1)	183 (65.8)	199 (68.2)	155 (72.8)	744 (69.3)	296 (69.0)	322 (72.5)	310 (73.1)	241 (77.0)	1,169 (72.6)
≥1, n (%)	84 (28.9)	95 (34.2)	93 (31.8)	58 (27.2)	330 (30.7)	133 (31.0)	122 (27.5)	114 (26.9)	72 (23.0)	441 (27.4)

Notes: ^aGOLD Stage II (moderate): FEV₁ ≥50% to <80% predicted and FEV₁/FVC <0.70.² ^bGOLD Stage III (severe): FEV₁ ≥30% to <50% predicted and FEV₁/FVC <0.70.²

Abbreviations: AB, aclidinium bromide; FEV₁, forced expiratory volume in 1 second; FF, formoterol fumarate.

References

1. Singh D, Jones PW, Bateman ED, et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. *BMC Pulm Med.* 2014;14(1):178.
2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2018. Available from: https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf Accessed October 11, 2018.